Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | PREP | P48147 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4702140 | 0.82 | NR1H2 (0.39) | CHRM2CHRM1CHRM3GPR119KDM4E | |
| SCHEMBL4754148 | 0.72 | ALDH1A1 (0.37) | GPR119KDM4EMAPTTHRBJAK2 | |
| SCHEMBL14790378 | 0.71 | NR1H2 (0.37) | CHRM2CHRM1CHRM3GPR119KDM4E | |
| SCHEMBL20005947 | 0.68 | HTRA1 (0.50) | GPR119KDM4ENR1H2JAK2JAK1 | |
| SCHEMBL25944417 | 0.68 | CHRM2 (0.50) | CHRM2CHRM1CHRM3GPR119KDM4E | |
| SCHEMBL25417641 | 0.67 | NR1H2 (0.47) | CHRM2CHRM1CHRM3MAPTNR1H2 | |
| SCHEMBL2277430 | 0.67 | NR1H2 (0.44) | CHRM2CHRM1CHRM3MAPTNR1H2 | |
| SCHEMBL23795442 | 0.67 | DDB1 (0.36) | CHRM2CHRM1CHRM3GPR119KDM4E | |
| SCHEMBL30444166 | 0.67 | DDB1 (0.36) | CHRM2CHRM1CHRM3GPR119KDM4E | |
| SCHEMBL20005725 | 0.67 | DPP4 (0.40) | CHRM2CHRM1CHRM3GPR119KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1909575-A2 | SUBSTITUTED N-CINNAMYL BENZAMIDES | ChemoCentryx Inc (US) | 2008-04-16 | — | — | EP | disclosed |
| US-20070021484-A1 | Substituted N-cinnamyl benzamides | CHEMOCENTRYX, INC. (US) | 2007-01-25 | — | — | US | disclosed |
| WO-2007002842-A2 | SUBSTITUTED N-CINNAMYL BENZAMIDES | CHEMOCENTRYX, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021484-A1 | Substituted N-cinnamyl benzamides | BRDT, BCCIP, NAT10 | CHRM2 4871/4885CHRM1 4881/4885CHRM3 4820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.